Targeting inflammaging to inhibit endothelial injury and ARDS development in aging lungs - acute respiratory distress syndrome (ARDS) is a form of acute-onset hypoxemic respiratory failure with…

Active Grant Awarded

Award ID
R01HL187966
Recipient
Awarding agency
Obligated
$778,202

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 6% complete
Place of performance
Chicago, IL 60611, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute awarded Grant R01HL187966 to Ann & Robert H Lurie Children's Hospital of Chicago, with $778,202 obligated, on August 26, 2026. The award falls under the Cardiovascular Diseases Research program (CFDA 93.837). The funded work examines how aging drives endothelial injury in acute respiratory distress syndrome (ARDS), a condition the source describes as having mortality rates as high as 40% and no effective treatment. The project hypothesizes that endothelial senescence induces NOX2 expression, which augments excessive reactive oxygen species production, leading to endothelial apoptosis and lung injury.

The supporting data cited in the source show that endothelial NOX2 expression rises in aged mice at baseline and after lipopolysaccharide challenge, and that endothelial NOX2 knockout markedly inhibited inflammatory lung injury after sepsis challenge in aged mice. A NOX2-specific inhibitor administered to aged mice also markedly inhibited lung injury after lipopolysaccharide challenge. The source further reports in vitro induction of NOX2 expression by endothelial senescence in cultured human lung microvascular endothelial cells, and increased NOX2 expression in vascular endothelial cells of lung tissue from aged COVID-19 patients compared with middle-aged patients.

The period of performance runs from August 26, 2026 through an ultimate completion date of May 31, 2030. The place of performance is Chicago, IL 60611, USA.

Description

Targeting inflammaging to inhibit endothelial injury and ARDS development in aging lungs - acute respiratory distress syndrome (ARDS) is a form of acute-onset hypoxemic respiratory failure with bilateral pulmonary infiltrates, which is caused by acute inflammatory edema of the lungs not attributable to left heart failure. Despite improvements in supportive care for patients, there is currently no effective treatment for ARDS, and mortality rates for patients with ARDS are as high as 40%. A fundamental pathological change found in ARDS that results from sepsis is injury to the endothelial barrier, and, as a result, increased vascular permeability to protein. Aging is an important risk factor of ARDS. Compared to young adult patients, the incidence of ARDS resulting from sepsis or pneumonia in elderly patients (≥ 70 YR) is as much as 20-fold higher and the mortality rate is 10-fold higher. However, the underlying causes are poorly understood, and crucially little is known about how aging influences mechanisms of endothelial injury. Our supporting data show that endothelial nadph oxidase 2 (NOX2) but not NOX4 expression was markedly increased in aged mice at basal and also following lipopolysaccharide (LPS, I.P.) challenge. Knockout of endothelial NOX2 in aged mice leads to marked inhibition of inflammatory lung injury following sepsis challenge. In vitro study shows endothelial senescence induces NOX2 expression in cultured human lung microvascular ECS (HLMVECS). Importantly, we observed marked increase of NOX2 expression in vascular ECS of lung tissues from aged covid-19 patients compared to middle-age (e.g. 50S) patients, demonstrating the clinical relevance of our findings. Pharmacological treatment of aged mice with a NOX2-specific inhibitor markedly inhibited lung injury following LPS (I.P.) challenge. Thus, we hypothesize that endothelial senescence-induced NOX2 expression in ECS augments excessive ROS production leading to extensive endothelial apoptosis and endothelial injury which exaggerates inflammatory lung injury and mortality following sepsis challenge and targeting endothelial NOX2 is a novel precise therapeutic approach for prevention and treatment of ARDS in elderly patients. In AIM1, we will determine the role of endothelial NOX2 in mediating severe lung vascular injury and lung injury in aged mice following sepsis challenge. Studies in aim 2 will delineate the molecular mechanisms responsible for aging-induced NOX2 expression and explore the therapeutic potential of selective targeting of endothelial NOX2 as a precision approach for prevention and/or treatment of ARDS in elderly patients. Based on the clinical relevance of our findings, successful completion of the project will provide not only novel understanding of the molecular mechanisms of severe lung injury and greater mortality of elderly patients following sepsis but also novel targeted therapy to prevention and treatment of ARDS in elderly patients.

Quick answers

Who received award R01HL187966?

R01HL187966 was awarded to ANN & Robert H Lurie Childrens Hospital Of Chicago by National Heart Lung and Blood Institute (National Institutes of Health) on August 26, 2026.

How much is award R01HL187966 worth?

$778,202 has been obligated on R01HL187966.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award